Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging technology plans to make a difference.
180 Markets is Australia’s ultimate resource for knowledge and access to all ASX capital raises.
Questions about this interview or other inquiries, please contact us.
https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Imagion’s CEO, Isaac Bright, presents our latest investor opportunities at ShareCafe’s Hidden Gems Webinar on 20 October 2023. https://youtu.be/XCfQ64VeVCg Video Transcript: First up, we have
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
